BIO Asia–Taiwan 2023 亞洲生技大會

BIO Asia–Taiwan 2023 亞洲生技大會


Chin-Ming Chang

Session 7 – Sharing Biotech Successes-Taiwan BIO Awardee Showcase

Date:27 July (Thursday)
Time:10:40 – 12:10 (GMT+8)

Chin-Ming Chang

Chief Executive Officer
TaiMed Biologics Inc

Dr. Chin-Ming Chang is a distinguished thought leader and expert in the field of biotechnology and pharmaceuticals, recognized for his significant contributions to the development and commercialization of innovative therapies targeting various medical conditions such as infectious diseases, ophthalmology, Alzheimer's disease, and osteoporosis. Currently serving as the CEO of TaiMed Biologics, Dr. Chang leads the company in its mission to pioneer groundbreaking treatments for HIV.

Driven by a desire to save lives and combat diseases. Dr. Chang displayed a deep interest in the field of pharmaceuticals since young. He completed his undergraduate studies at the National Taiwan University, where he earned a B.S. in Pharmacy. Building upon his foundational knowledge, Dr. Chang pursued advanced studies and obtained a Ph.D. in Pharmaceutics from the University of Texas at Austin.

Following the completion of his education, Dr. Chang embarked on a fruitful career in the biotechnology industry. He gained invaluable experience and expertise through various scientific and leadership roles at esteemed companies such as Eli Lilly and Allergan. Eventually, his remarkable skills and knowledge led him to join TaiMed Biologics, where he swiftly ascended through the ranks and become the CEO.

Dr. Chang's visionary mindset and unwavering commitment to scientific excellence have played a pivotal role in establishing TaiMed as a prominent player within the biopharmaceutical industry. Under his guidance, TaiMed achieved remarkable milestones, notably the successful commercialization of Trogarzo, the world's first and only monoclonal antibody (mAb)-based drug product for the treatment of multi-drug resistant HIV patients. Trogarzo has provided renewed hope and improved health outcomes for individuals battling this challenging condition.

Continuing his pursuit of innovation, Dr. Chang spearheads TaiMed’s efforts to develop the world's first and only mAb-based long-acting combination therapy for HIV. This groundbreaking therapy holds tremendous potential to revolutionize HIV treatment and improve the lives of countless individuals affected by the disease.

Over the past five years, Dr. Chang has played a crucial role in driving the advancement of TaiMed's research and development pipeline, overseeing the successful commercialization of Trogarzo, and leading the establishment of their GMP manufacturing facility and CDMO services. His exceptional leadership and scientific acumen continue to shape the trajectory of TaiMed Biologics, positioning the company at the forefront of biopharmaceutical innovation and healthcare advancement.

Overall, Dr. Chin-Ming Chang's remarkable contributions, visionary approach, and dedication to scientific excellence have solidified his reputation as a key thought leader in the biotechnology and pharmaceutical fields. His transformative work at TaiMed Biologics reflects his unwavering commitment to developing innovative therapies that have the potential to transform the lives of patients worldwide.

Company Profile

TaiMed Biologics’ mission is to redefining HIV treatment with innovative breakthrough therapies

TaiMed Biologics is a pioneering biopharmaceutical company based in Taiwan that is dedicated to revolutionizing HIV treatment through the development of innovative breakthrough therapies. With involvement spanning various stages, from research and development to manufacturing and commercialization, TaiMed has established itself as a leading player in HIV drug development.

In March 2018, TaiMed achieved a significant milestone with the regulatory approval and market launch of its groundbreaking HIV drug, Trogarzo, by the US Food and Drug Administration (FDA). Trogarzo stands as the world's first and only monoclonal antibody-based drug approved for the treatment of HIV, making it a game-changer in the field of HIV therapeutics. This accomplishment positioned TaiMed as the first Taiwanese company to receive FDA approval for a Biologics License Application (BLA), cementing its status as one of the most prominent biopharmaceutical companies in Taiwan.

Building upon this success, TaiMed is now directing its efforts toward the development of a revolutionary long-acting mAb-based combination therapy, aiming to capture a significant market share for first-line maintenance therapy in HIV. With an ambitious annual revenue target of over 10 billion US dollars, TaiMed aspires to become a world-class and highly specialized HIV drug development company, addressing the unmet medical needs of patients worldwide.

In addition to its internal research and development programs, TaiMed has leveraged its expertise and capabilities as a Contract Development and Manufacturing Organization (CDMO). Through its CDMO division, TaiMed offers comprehensive services to clients in the pharmaceutical industry. These services include formulation development, process optimization, and large-scale manufacturing for antibody production. By combining its proficiency in HIV drug development with its CDMO capabilities, TaiMed is strategically positioned to provide valuable support to clients seeking to bring their products from development to market. The company assists with regulatory compliance, manufacturing scale-up, and ensures the highest quality standards throughout the production process.

As of today, TaiMed Biologics continues to advance its mission, actively pursuing innovative therapies to combat HIV while simultaneously offering its expertise to clients in the pharmaceutical industry. Through its relentless pursuit of excellence and commitment to improving patients' lives, TaiMed Biologics is reshaping the landscape of HIV treatment and solidifying its position as a leader in biopharmaceutical innovation.